Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31399502 | 0.98 | DUT (0.37) | DUTCYP4F2CYP4A11 | |
| SCHEMBL16124200 | 0.98 | DUT (0.37) | DUTCYP4F2CYP4A11 | |
| SCHEMBL8622940 | 0.98 | DUT (0.37) | DUTCYP4F2CYP4A11 | |
| SCHEMBL1143253 | 0.98 | DUT (0.37) | DUTCYP4F2CYP4A11 | |
| SCHEMBL200311 | 0.98 | DUT (0.37) | DUTCYP4F2CYP4A11 | |
| SCHEMBL25304378 | 0.98 | DUT (0.37) | DUTCYP4F2CYP4A11 | |
| SCHEMBL28500270 | 0.98 | DUT (0.37) | DUTCYP4F2CYP4A11 | |
| SCHEMBL7539972 | 0.98 | DUT (0.37) | DUTCYP4F2CYP4A11 | |
| SCHEMBL10930589 | 0.98 | DUT (0.37) | DUTCYP4F2CYP4A11 | |
| SCHEMBL571057 | 0.93 | DUT (0.39) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12623988-B2 | Scaleable preparation of polyketides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-12 | — | — | US | disclosed |
| US-12473295-B2 | Substituted straight chain spiro derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-18 | — | — | US | disclosed |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4577526-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-120051461-A | VHH antibody conjugates | 雅博得乐医疗公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250145608-A1 | KRAS DEGRADING COMPOUNDS COMPRISING ANNULATED 2-AMINO-3-CYANO THIOPHENES | BOEHRINGER INGELHEIM INTL GMBH CORP (DE) | 2025-05-08 | — | — | US | disclosed |
| CN-119630672-A | Camptothecin derivative and conjugate thereof, and preparation method and medical application thereof | 一线医药（杭州）有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0360246-B1 | 3-Oxiranyl benzoic acids and derivatives thereof | SEARLE & CO (US) | 1994-03-30 | — | — | EP | disclosed |
| US-5272171-A | Phosphonooxy and carbonate derivatives of taxol | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0558959-A1 | Phosphonooxy and carbonate derivatives of taxol | Bristol-Myers Squibb Company (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0532423-A1 | Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0531597-A1 | Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5190964-A | 5-fluorocarbacyclins, their preparation and pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-03-02 | — | — | US | disclosed |
| EP-0113311-B1 | 5-FLUOROCARBACYCLINS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-01-02 | — | — | EP | disclosed |
| EP-0360246-A1 | 3-Oxiranyl benzoic acids and derivatives thereof | G.D. Searle & Co. (US) | 1990-03-28 | — | — | EP | disclosed |
| EP-0113311-A1 | 5-Fluorocarbacyclins, process for their preparation and their use as medicines | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | DUT 60/4885CYP4F2 4833/4885CYP4A11 4851/4885 |
| US-12623988-B2 | Scaleable preparation of polyketides | SF3B5, RPS5, RPS25 | DUT 519/4885CYP4F2 1770/4885CYP4A11 1162/4885 |
| US-12473295-B2 | Substituted straight chain spiro derivatives | MLLT1, MEN1, MLLT3 | DUT 4220/4885CYP4F2 3559/4885CYP4A11 3202/4885 |
| US-20250145608-A1 | KRAS DEGRADING COMPOUNDS COMPRISING ANNULATED 2-AMINO-3-CYANO THIOPHENES | KRAS, NRAS, TP53 | DUT 1070/4885CYP4F2 815/4885CYP4A11 608/4885 |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | DUT 60/4885CYP4F2 4833/4885CYP4A11 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.